Impact of Sex and Genetic Variation in Relevant Pharmacogenes on the Pharmacokinetics and Safety of Valsartan, Olmesartan and Hydrochlorothiazide

Impact of Sex and Genetic Variation in Relevant Pharmacogenes on the Pharmacokinetics and Safety of Valsartan, Olmesartan and Hydrochlorothiazide

Drug combination therapy is the most common pharmacological strategy for hypertension management. No pharmacogenetic biomarkers for guiding hypertension pharmacotherapy are available to date. The study population were 64 volunteers from seven bioequivalence trials investigating formulations with val...

Full description

Bibliographic Details
Main Authors:	Paula Soria-Chacartegui, Pablo Zubiaur, Dolores Ochoa, Marcos Navares-Gómez, Houwaida Abbes, Gonzalo Villapalos-García, Alejandro de Miguel, Eva González-Iglesias, Andrea Rodríguez-Lopez, Gina Mejía-Abril, Samuel Martín-Vilchez, Sergio Luquero-Bueno, Manuel Román, Francisco Abad-Santos
Format:	Article
Language:	English
Published:	MDPI AG 2023-10-01
Series:	International Journal of Molecular Sciences
Subjects:	valsartan olmesartan hydrochlorothiazide pharmacogenetics <i>ABCB1</i> and <i>SLC22A1</i>
Online Access:	https://www.mdpi.com/1422-0067/24/20/15265

Similar Items

EVALUATION OF ANTIHYPERTENSIVE THERAPY WITH THE COMBINATION OF OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
by: Steven G. Chrysant, et al.
Published: (2011-06-01)

Development of a Discriminative Dissolution Method, Using In-Silico Tool for Hydrochlorothiazide and Valsartan Tablets
by: Rosmery Merma Leon, et al.
Published: (2023-06-01)

Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process
by: Mac Arturo Murillo-Fernández, et al.
Published: (2022-02-01)

Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers
by: Arvind Kumar, et al.
Published: (2019-07-01)

Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial
by: Sua Jo, et al.
Published: (2022-01-01)

EFFICACY OF FIXED COMBINATION OF VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN COMPLEX THERAPY OF THE PATIENT OF VERY HIGH CARDIOVASCULAR RISK
by: I. M. Sokolov, et al.
Published: (2015-12-01)

A Selective and Accurate LC-MS/MS Method for Simultaneous Quantification of Valsartan and Hydrochlorothiazide in Human Plasma
by: Anzarul Haque, et al.
Published: (2023-02-01)

Application of an LC–MS/MS method for the analysis of amlodipine, valsartan and hydrochlorothiazide in polypill for a bioequivalence study
by: Jaivik V. Shah, et al.
Published: (2017-10-01)

The first results of an international clinical trial VICTORY:the efficacy and safety of antihypertensive valsartan monotherapy and the fixed combination of valsartan and hydrochlorothiazide usingdifferent dosage regimens in patients with 1-2 degree arterial hypertension
by: E Evgen'evna Chazova, et al.
Published: (2015-06-01)

Continuous wavelet transform methods for the simultaneous determinations and dissolution profiles of valsartan and hydrochlorothiazide in tablets
by: Erdal Dinç, et al.
Published: (2017-04-01)

The results of the international clinical study VICTORY:efficacy and safety of antihypertensive monotherapy with valsartan (Valsacor®) and its fixed combination with hydrochlorothiazide(Valsacor® H)in routine clinical practice in patients with hypertens
by: Chazova I.E., et al.
Published: (2017-05-01)

The results of the international clinical study VICTORY: efficacy and safety of antihypertensive monotherapy with valsartan (Valsacor®) and its fixed combination with hydrochlorothiazide (Valsacor® H) in routine clinical practice in patients with grade 1 and grade 2 hypertension
by: I E Chazova, et al.
Published: (2017-06-01)

The effectiveness of therapy with valsartan and hydrochlorothiazide and its effect on the left atrial myocardium condition in women with arterial hypertension in postmenopause
by: M. Yu. Kolesnyk, et al.
Published: (2019-12-01)

The Distribution of the Genotypes of <i>ABCB1</i> and <i>CES1</i> Polymorphisms in Kazakhstani Patients with Atrial Fibrillation Treated with DOAC
by: Ayan Abdrakhmanov, et al.
Published: (2023-05-01)

Association between <i>ABCB1</i> rs2235048 Polymorphism and THC Pharmacokinetics and Subjective Effects following Smoked Cannabis in Young Adults
by: Justin Matheson, et al.
Published: (2022-09-01)

Hydrochlorothiazide
by: 982 SIRIM

Real-world evidence on the strategy of olmesartan-based triple single-pill combination in Korean hypertensive patients: a prospective, multicenter, observational study (RESOLVE-PRO)
by: Il Suk Sohn, et al.
Published: (2021-11-01)

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (<i>DPYD</i>) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
by: Paula Soria-Chacartegui, et al.
Published: (2021-11-01)

PHARMACOECONOMIC ANALYSIS OF OLMESARTAN THERAPY IN THE INDIVIDUAL–LEVEL MANAGEMENT OF ARTERIAL HYPERTENSION
by: S. G. Gorokhova, et al.
Published: (2012-08-01)

Comparative effects of valsartan plus cilnidipine or hydrochlorothiazide on nocturnal home blood pressure
by: Takeshi Fujiwara, et al.
Published: (2021-03-01)

Validated stability-indicating HPLC-DAD method of analysis for the antihypertensive triple mixture of amlodipine besylate, valsartan and hydrochlorothiazide in their tablets
by: Rasha A. Shaalan, et al.
Published: (2017-02-01)

Genetic Variation in <i>CYP2D6</i> and <i>SLC22A1</i> Affects Amlodipine Pharmacokinetics and Safety
by: Paula Soria-Chacartegui, et al.
Published: (2023-01-01)

Hydrochlorothiazide tablets
by: 982 SIRIM

The choice of antihypertensive therapy in correction of cognitive impairments and prevention of dementia: possibilities of valsartan and fixed-dose combination of valsartan and hydrochlorothiazide
by: O D Ostroumova, et al.
Published: (2016-12-01)

The choice of antihypertensive therapy in correction of cognitive impairments and prevention of dementia: possibilities of valsartan and fixed-dose combination of valsartan and hydrochlorothiazide
by: Ostroumova O.D., et al.
Published: (2016-12-01)

Complete Characterization of Degradation Byproducts of Olmesartan Acid, Degradation Pathway, and Ecotoxicity Assessment
by: Giovanni Luongo, et al.
Published: (2021-06-01)

Identification of Transporter Polymorphisms Influencing Metformin Pharmacokinetics in Healthy Volunteers
by: Miriam Saiz-Rodríguez, et al.
Published: (2023-03-01)

Twenty‐Four‐Hour Blood Pressure‐Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double‐Blind Multicenter Study
by: Kazuomi Kario, et al.
Published: (2023-04-01)

Enteropatía por olmesartán
Published: (2017-12-01)

Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia
by: Juan Eduardo Megías-Vericat, et al.
Published: (2022-04-01)

<i>CYP2D6</i> Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients
by: Jemal Hussien Ahmed, et al.
Published: (2019-09-01)

LC and NMR Studies for Identification and Characterization of Degradation Byproducts of Olmesartan Acid, Elucidation of Their Degradation Pathway and Ecotoxicity Assessment
by: Giovanni Luongo, et al.
Published: (2021-03-01)

Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites
by: Yuanhuang Chen, et al.
Published: (2021-06-01)

Olmesartan-induced enteropathy
by: Sofia Moura de Azevedo, et al.
Published: (2023-01-01)

Effects of <i>SLCO1B1</i> and <i>SLCO1B3</i> Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers
by: Gonjin Song, et al.
Published: (2021-08-01)

Olmesartan-Associated Enteropathy: An Unexpected Cause of Chronic Diarrhoea
by: Mónica Martins Teixeira, et al.
Published: (2019-04-01)

Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy
by: Andrea Giacomelli, et al.
Published: (2018-11-01)

Probable interacción entre Olmesartán y Rosuvastatina por inhibición de OATP1B1
by: Rodríguez Arcas MJ
Published: (2018-12-01)

Olmesartan/amlodipine: a review of its use in the management of hypertension
by: Kreutz R
Published: (2011-03-01)

Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? – A Case Report
by: Jeiziner C, et al.
Published: (2022-05-01)